Venous Thromboembolism

The prevalence rate of VTE was 2% among a large population of SCD patients in Nigeria.

Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively

In a population aged 70 years and older, a remote history of VT was associated with an increased risk of VT independent of other factors.

Apixaban prescription beyond 90 days showed no difference in hospitalization risk for major bleeding.

Investigators noted that clinically relevant risks could not be excluded with certainty despite not seeing a statistically significant increase in corresponding risks for more rare and severe thrombotic outcomes.

A recent study showed anticoagulant therapy for 6 weeks compared to 3 months met noninferiority criteria, based on a combination of recurrent VTE risk and bleeding risk.

Recurrent VTE shows a higher rate than expected for patients with subsegmental pulmonary embolism without proximal deep vein thrombosis managed without anticoagulation.

Patients with history of VTE, peak D-dimer ≥3 μg/mL, and predischarge CRP ≥10 mg/dL were at high risk of experiencing new onset of VTE after hospital discharge.

Incidence rates of post-Ad26.COV2.S vaccination cerebral venous sinus thrombosis was 8.65 per 100,000 person-years.

Analysis data show 3 times more risk of intensive care unit care in patients with venous thromboembolism compared to non-VTE patients (RR: 2.78).

Data show postoperative initiation of factor XI inhibition was effective method for reducing the risk of VTE following total knee arthroplasty.

The FDA Cardiovascular and Renal Drugs Advisory Committee cited concerns over an increase in thrombotic events.

Dabigatran etexilate was approved in both oral pellet and capsule forms for varying pediatric patient populations.

The anticoagulant did not improve clinical outcomes when compared with prophylactic anticoagulation.

Patients on atorvastatin experienced similar rates of adjudicated venous thromboembolism and all-cause mortality compared to placebo.

A new study finds patients with atrial fibrillation or venous thromboembolism were at higher risk of increased bleeding and hospitalization when treated with combination DOAC and aspirin.

FDA, CDC recommended halting use of the one-shot vaccine at all federal sites.

Investigators evaluated patients from 3 Chicago hospital systems and assessed risk factors associated with thrombosis.

Liquidia Technologies plans on addressing FDA concerns regarding treprostinil.

Compared with prophylaxis anticoagulation, full dose anticoagulation provided a greater survival benefit to those in a predominantly black population.

The risk of VTE is increased in both hospitalized and non-hospitalized COVID-19 patients.

For obese patients, both weight gain and loss was linked to an increase in the rate of incident venous thromboembolism.

Treatments for VTE in children fall short as they require frequent monitoring and include unpredictable food and drug interactions.

Post-discharge thromboprophylaxis is not necessary.

The rate of adverse events was higher in patients suffering from both deep vein thrombosis and pulmonary embolisms than it was in just patients with DVT.

Future studies are needed to develop and validate better risk assessment tools.

Guideline adoption could lead to more use of thrombolytic therapy.

The study paves the way for prospective multi-institutional randomized control trials to further re-enforce the safe use of direct oral anticoagulants in patients with obesity.

Patients with a mPAP of at least 19 mm Hg and pulmonary artery wedge pressure of 15 mm Hg or less had an adjusted hazard ratio for mortality of 1.71.

A new systematic review and meta-analysis challenges the notion that preventing VTE is associated reduced mortality risk.